Written question asked by Lord Hunt of Kings Heath (Labour) on Monday, 2 March 2026, in the House of Lords. It was due for an answer on Monday, 16 March 2026. It was answered by Baroness Merron (Labour) on Wednesday, 11 March 2026 on behalf of the Department of Health and Social Care.
Liothyronine
- Question
-
To ask His Majesty's Government what assessment they have made of whether all integrated care boards adhere to NHS England's national guidance on liothyronine.
- Answer
-
The inclusion of liothyronine in the guidance will be reviewed only if there is a significant change in the evidence, including National Institute for Health and Care Excellence (NICE) guidance on the assessment and management of thyroid disease, which currently aligns with the policy guidance recommendations.
No assessment of integrated care boards’ adherence to guidance has been made. Regions cascaded the ‘items that should not be prescribed in primary care’ policy guidance to systems who are responsible for ensuring prescribing is in line with the available guidance.
The Department and NHS England do not collect or hold this data, as integrated care boards make exceptional funding requests for liothyronine, and therefore the information would be held by individual integrated care boards.
Secondary information
- Type
- Written question
- Reference
- HL15039
- Session
- 2024-26
- Grouped for answer
- Yes
- Subjects
- Integrated care boards Liothyronine
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2026-03-11 14:32:37 +0000
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/lords/2024-26/HL15039
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/lords/2024-26/HL15039
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/lords/2024-26/HL15039